Literature DB >> 1859086

Band 3 in aging and neurological disease.

M M Kay1.   

Abstract

Senescent cell antigen appears on old cells and marks them for death by initiating the binding of IgG autoantibody and subsequent removal by phagocytes in mammals and other vertebrates. We have created a synthetic aging antigen that blocks binding of IgG to senescent cells in vitro. Synthetic senescent cell antigen might be effective in preventing cellular destruction in vivo in certain diseases, and can be used to manipulate cellular life span in situ. Senescent cell antigen is generated by the modification of an important structural and transport membrane molecule, protein band 3. Band 3 is present in cellular, nuclear, Golgi, and mitochondrial membranes as well as in cell membranes. Band 3 proteins in nucleated cells participate in cell surface patching and capping. Band 3 maintains acid-base balance by mediating the exchange of anions (e.g., chloride, bicarbonate), and is the binding site for glycolytic enzymes. It is responsible for CO2 exchange in all tissues and organs. Thus, it is the most heavily used anion transport system in the body. Band 3 is a major transmembrane structural protein which attaches the plasma membrane to the internal cell cytoskeleton by binding to band 2.1 (ankyrin). Oxidation generates senescent cell antigen in situ. Band 3 is present in the central nervous system, and differences have been described in band 3 between young and aging brain tissue. One autosomal recessive neurological disease, choreoacanthocytosis, is associated with band 3 abnormalities. The 150 residues of the carboxyl terminus segment of band 3 appear to be altered. In brains from Alzheimer's disease patients, antibodies to aged band 3 label the amyloid core of classical plaques and the microglial cells located in the middle of the plaque in tissue sections, and an abnormal band 3 in immunoblots. Band 3 protein(s) in mammalian brain performs the same functions as that of erythroid band 3. These functions is anion transport, ankyrin binding, and generation of senescent cell antigen, an aging antigen that terminates the life of cells. Structural similarity of brain and erythroid band 3 is suggested by the reaction of antibodies to synthetic peptides of erythroid band 3 with brain band 3, the inhibition of anion transport by the same inhibitors, and an equal degree of inhibition of brain and erythrocyte anion transport by synthetic peptides of erythroid band 3. One of these segments, pep-COOH, contains antigenic determinants of senescent cell antigen.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859086     DOI: 10.1111/j.1749-6632.1991.tb16979.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Vitamin E prevents oxidative modification of brain and lymphocyte band 3 proteins during aging.

Authors:  J E Poulin; C Cover; M R Gustafson; M B Kay
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

2.  Molecular mapping of human band 3 aging antigenic sites and active amino acids using synthetic peptides.

Authors:  M M Kay
Journal:  J Protein Chem       Date:  1992-12

3.  Immune responses to band 3 neoantigens on Plasmodium falciparum-infected erythrocytes in subjects living in an area of intense malaria transmission are associated with low parasite density and high hematocrit value.

Authors:  B Hogh; E Petersen; I Crandall; A Gottschau; I W Sherman
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

4.  Structural alterations of the erythrocyte membrane proteins in diabetic retinopathy.

Authors:  Ioannis K Petropoulos; Panagiotis I Margetis; Marianna H Antonelou; John X Koliopoulos; Sotirios P Gartaganis; Lukas H Margaritis; Issidora S Papassideri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08       Impact factor: 3.535

5.  Clinical and molecular research of neuroacanthocytosis.

Authors:  Lihong Zhang; Suping Wang; Jianwen Lin
Journal:  Neural Regen Res       Date:  2013-03-25       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.